Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio(University of Siena), Bohuslav Melichar(Palacký University Olomouc), Jeremy Power, Ivana Krajsová(Charles University), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Mario Mandalà(University of Perugia), Karl D. Lewis(University of Colorado Denver), Craig Underhill(AstraZeneca (United Kingdom)), Lev Demidov(Heidelberg University), Rachel Roberts‐Thomson(Queen Elizabeth Hospital), Véronique Buyse, Alexander Guminski(The University of Sydney), Gabriela Cinat(German Cancer Research Center), Jeroen Mebis(Jessa Hospital), Eugen Kubala, Kerry J. Savage(Spinal Cord Injury BC), Igor Bondarenko(Dnipro State Medical University), Michael P. Brown(South Australia Pathology), Nathalie Blockx, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrzej Maćkiewicz(Poznan University of Medical Sciences), Petr Arenberger(Charles University), Dirk Schadendorf(National Center for Tumor Diseases), Thomas Berger, Suresh Varma, Nicolas Lazaretti, Stjepko Pleština, Željko Vojnović, Catalin Mihalcioiu(McGill University Health Centre), Catriona M. McNeil(Chris O’Brien Lifehouse), Grant R. Goodman(Melanoma Institute Australia), Luis Fein(National Cancer Center), Sérgio Jobim Azevedo(Hospital de Clínicas de Porto Alegre), Shahneen Sandhu(The University of Melbourne), Nina Dabelić, Fábio Franke(National Cancer Center), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Brian Simmons, Andrew Haydon(The Alfred Hospital), Ralph Wong(CancerCare Manitoba), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Teresa M. Petrella, Xinni Song, Yibing Yan(Anhui Medical University), Christopher Herbert(At Bristol), Adnan Khattak(Edith Cowan University), Phillip Parente(Cornell University), Chenglin Ye(Wuhan University), Ivo Kocák
The Lancet Oncology
February 21, 2018
10.1016/s1470-2045(18)30106-2
Cited by 216

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k